Maho Yamashita Selected Research

Maho Yamashita Research Topics

3	Chronic Renal Insufficiency 11/2017 - 01/2013
3	Vascular System Injuries 09/2014 - 05/2013
2	Type 2 Diabetes Mellitus (MODY) 01/2019 - 01/2013
1	Renal Tubular Acidosis (Distal Renal Tubular Acidosis) 12/2021
1	Autoimmune Hepatitis 08/2021
1	Oral Ulcer (Mouth Ulcer) 08/2021
1	Alopecia (Baldness) 08/2021
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2021
1	Hypertrophy 01/2019
1	Albuminuria 01/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Necrosis 01/2019
1	Proteinuria 02/2017
1	Reperfusion Injury 01/2016
1	Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I) 11/2015
1	Acute Kidney Injury (Acute Renal Failure) 01/2015
1	Cardiomegaly (Heart Hypertrophy) 09/2014
1	Vascular Diseases (Vascular Disease) 09/2014
1	Atherosclerosis 09/2014
1	Hyperglycemia 01/2013
1	Vascular Calcification 01/2013

3	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2014
2	Phosphates (Orthophosphate)IBA 11/2017 - 01/2013
2	CreatinineIBA 02/2017 - 01/2016
2	myocardinIBA 09/2014 - 05/2013
2	Differentiation AntigensIBA 05/2013 - 01/2013
1	NucleotidesIBA 12/2021
1	Azathioprine (Imuran)FDA LinkGeneric 08/2021
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2021
1	Fibronectins (Fibronectin)IBA 01/2019
1	nephrinIBA 02/2017
1	AlbuminsIBA 02/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2017
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016
1	Urea (Carbamide)FDA LinkGeneric 01/2016
1	NitrogenIBA 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 11/2015
1	AntioxidantsIBA 01/2015
1	HydrogenIBA 01/2015
1	trichostatin A (A 300)IBA 09/2014
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 09/2014
1	Atrial Natriuretic Factor (ANF)IBA 09/2014
1	Angiotensin IIIBA 09/2014
1	Kruppel-Like Factor 4IBA 09/2014
1	olmesartanIBA 09/2014
1	Histone Deacetylase InhibitorsIBA 09/2014
1	N-propionylprocainamideIBA 09/2014
1	Tamoxifen FDA LinkGeneric 01/2014
1	Glucose (Dextrose)FDA LinkGeneric 01/2013

1	Intravenous Administration 02/2017